Products Press Releases Partnering Careers Contact

Featured Post

Temporary Shortage of Quillivant® ER 20mg Chewable Tablets

May 19, 2025

May 19, 2025

Temporary Shortage of Quillivant® ER 20mg Chewable Tablets

May 1, 2025

Kye Pharmaceuticals Secures Exclusive Canadian License, Supply and Commercialization Agreement for a novel proton pump inhibitor (PPI) treatment option for gastroesophageal reflux disease (GERD) in infants, children and adults

April 8, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

March 11, 2025

ACCRUFeR® (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anemia.

August 29, 2024

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD

August 27, 2024

Kye Pharmaceuticals announces approval in Canada for ACCRUFeR® (ferric maltol) for the treatment of iron deficiency anemia in adult patients